The Liver Support Stack: NAC, TUDCA, Vitamin E, and Milk Thistle

← Back to articles

The "liver detox" supplement category is dominated by products with no clinical evidence and several with actual hepatotoxicity. A defensible liver-support stack uses supplements with hepatology trial data for specific indications: NAC for acetaminophen rescue and NAFLD, TUDCA for cholestatic/bile-acid contexts, vitamin E (PIVENS trial) for non-diabetic NASH, and silymarin for adjunctive support.

Layer 1: N-Acetylcysteine (NAC), 600 mg Twice Daily

NAC is the prescription antidote for acetaminophen overdose and has emerging NAFLD evidence at 600 mg twice daily reducing ALT and oxidative stress markers. Also tested in chronic liver disease with modest signal. The strongest evidence is in acute acetaminophen toxicity (IV protocol). See NAC overview and NAC dosing piece.

Layer 2: TUDCA (Tauroursodeoxycholic Acid), 250–500 mg Daily

TUDCA is the taurine-conjugated form of UDCA, the prescription drug for primary biliary cholangitis. TUDCA has positive trial signals in cholestatic liver conditions and is mechanistically interesting in NAFLD via ER-stress reduction. Trial evidence is smaller than UDCA's but mechanistic continuity is reasonable. Useful in adults with cholestatic patterns or as an adjunct in NAFLD.

Layer 3: Vitamin E, 800 IU Daily — Non-Diabetic NASH Only

The PIVENS trial (2010) in 247 non-diabetic adults with biopsy-proven NASH showed vitamin E 800 IU/day for 96 weeks produced significant histological improvement versus placebo. AASLD guidelines support vitamin E in non-diabetic adults with biopsy-proven NASH. Cap at 800 IU; chronic intake above this has small all-cause mortality signals in meta-analysis. See vitamin E NAFLD piece.

Layer 4: Silymarin (Milk Thistle), 420 mg Daily

Silymarin has small but reproducible ALT-reduction trial data in NAFLD and viral hepatitis. The newer EUDRAGIT-S formulations have better bioavailability than older powder products. Effect smaller than NAC or vitamin E but very clean safety profile and useful as an adjunct.

Layer 5 (Optional): Choline — For NAFLD Specifically

Choline deficiency is a recognized NAFLD driver. About 90% of US adults consume below the adequate intake. Supplementation with phosphatidylcholine 500-1,000 mg daily or choline bitartrate 500 mg daily addresses this. See choline piece.

What NOT to Take

Avoid green tea extract megadoses — case reports of acute hepatitis, particularly with concentrated EGCG. See green tea hepatotoxicity piece. Skip "liver cleanse" / "liver detox" formulas — many contain herbs with documented hepatotoxicity risk (kava, comfrey, certain Chinese herbs). Avoid high-dose niacin in NAFLD — worsens insulin resistance. Skip bodybuilding "anabolic support" supplements — frequent culprits in DILI. Avoid kava entirely — see our kava piece.

How to Run the Stack

Weight loss is the dominant NAFLD intervention — 5-10% body weight reduction reverses NASH histologically in many patients. Test ALT, AST, GGT, lipid panel, HbA1c. For non-diabetic biopsy-proven NASH: vitamin E 800 IU daily. For NAFLD broadly: NAC 600 mg BID + silymarin 420 mg daily. TUDCA for cholestatic component. Re-evaluate ALT and imaging at 6 months. Hepatology referral for advanced fibrosis. See NAFLD condition page.